Evaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in Cameroon

BMC Infectious Diseases

Basile Kollo¹  Patrick Sylvestre Bekoule²  Hortense Djidjou²  Cecile Sonkoue²  Cavin Epie Bekolo³ 

[1] Department of Public Health, University of Douala, PO Box 2701, Douala, Cameroon;Regional Hospital of Nkongsamba, PO Box 03, Nkongsamba, Cameroon;Centre Médical d’Arrondissement de Baré, P.O. Box 628, Nkongsamba, Cameroon

关键词: Cameroon;    Laboratory monitoring;    Antiretroviral therapy;    HIV;   

Others  :  1125504
DOI  :  10.1186/1471-2334-14-519

 received in 2014-06-14, accepted in 2014-09-22,  发布年份 2014

【 摘 要 】

Background

The antiretroviral therapy (ART) program of Cameroon recommends routine laboratory monitoring of haematological toxicity if a regimen contains zidovudine (AZT) and of hepatotoxicity for NVP-containing regimens on the 15^th day after ART initiation. This study aimed to assess the relevance of this repeated laboratory measurements considered to be precocious, inaccessible and unavailable in a resource limited setting.

Methods

A retrospective cohort of HIV-infected patients of age 15 years and above enrolled for first line ART at The Regional Hospital of Nkongsamba in Cameroon. We monitored liver transaminases and blood cell indices after two weeks of ART initiation for any significant change from baseline. Factors associated with abnormal changes were examined using a multivariable logistic regression model with random effects.

Results

Enrolled were 154 patients of whom 105 (68.2%) were females. The mean ALAT (alanine aminotransferase) level at baseline was 17.87 ± 20.48 U/L increasing to 19.25 ± 12.01 U/L at two weeks of follow-up (p = 0.53) while the mean ASAT (aspartate aminotransferase) level increased from 17.32 ± 11.87 U/L at baseline to 21.02 ± 14.12 U/L at two weeks of follow-up (p = 0.02). We observed a drop in the mean haemoglobin concentration from 10.86 ± 2.63 g/dL at baseline to 10.36 ± 1.92 g/dL at the second week of follow-up (p = 0.02). The prevalence of elevated liver enzymes and anaemia after two weeks of treatment were 7.5% and 39.2% respectively. Stavudine containing regimens were most likely to induce hepatotoxicity [adjusted Odd Ratio (aOR) = 36.52, 95% CI: 1.44-924.38, p=0.029]. Baseline anaemia (aOR=60.08, 95% CI: 13.36-270.20, p < 0.0001) and body weight ≥ 60kg (aOR=0.28, 95% CI: 0.09-0.83, p = 0.02) were associated with anaemia at follow-up.

Conclusion

There was no significant rise in the mean level of transaminases and thus scheduling their routine monitoring at the end of the second week could be skipped. Conversely, the drop in mean haemoglobin level had little clinical importance but the high prevalence of anaemia after a fortnight on treatment suggests a targeted instead of a routine monitoring; focusing on the high risk population with baseline anaemia and low body weight.

【 授权许可】

   
2014 Bekolo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Joint United Nations Programme on HIV/AIDS (UNAIDS): Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva: UNAIDS; 2013.
• [2]World Health Organization: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization 2013; 2013.
• [3]National Institute of Statistics: Enquête Démographique et de Santé et à Indicateurs Multiples EDS-MICS 2011. Yaounde: National Institute of Statistics; 2011.
• [4]Ministere de la Sante Publique du Cameroun: Rapport annuel des activités de lutte contre le VIH et les IST au Cameroun. Yaounde: Ministere de la Sante Publique du Cameroun; 2011.
• [5]Ministere de la Sante Publique du Cameroun: Directives nationales de prise en charge par les antirétroviraux des personnes (Adultes et Adolescents) infectées par le VIH. Yaounde: Ministere de la Sante Publique du Cameroun; 2010.
• [6]Kalyesubula R, Kagimu M, Opio K, Kiguba R, Semitala C, Schlech W, Katabira E: Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci 2011, 11(1):16-23.
• [7]Bekolo CE, Webster J, Batenganya M, Sume GE, Kollo B: Trends in mortality and loss to follow-up in HIV care at the Nkongsamba Regional hospital, Cameroon. BMC Res Notes 2013, 6:512. BioMed Central Full Text
• [8]Koenig SP, Schackman BR, Riviere C, Leger P, Charles M, Severe P, Lastimoso C, Colucci N, Pape JW, Fitzgerald DW: Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Clin Infect Dis 2010, 51(5):600-608.
• [9]Central Bureau of the Census and Population Studies: La population du Cameroun en 2010. Yaounde: Central Bureau of the Census and Population Studies; 2010.
• [10]Pollard R, Robinson P, Dransfield K: Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998, 20:1071-1092.
• [11]Martinez E, Blanco J, Arnaiz J: Hepatotoxicity in HIV-1–infected patients receiving nevirapine-containing antiretroviral therapy. AIDS (London, England) 2001, 15:1261-1268.
• [12]Stern J, Robinson P, Love J, Lanes S, Imperiale M, Mayers D: A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003, 34(Suppl 1):S21-S33.
• [13]Wit F, Weverling G, Jurriaans S, Lange J: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002, 186:23-31.
• [14]Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N: Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007, 45(8):1093-1101.
• [15]Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD Jr, Pape JW, Fitzgerald DW: Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005, 353(22):2325-2334.
• [16]Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, Mane AA, Bhagat S: Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr 2004, 37(5):1566-1569.
• [17]Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S: Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004, 87(7):760-767.
• [18]Shah I: Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr 2006, 52(4):244-248.
• [19]Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X: Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d’Ivoire. Antivir Ther 2005, 10(5):615-624.
• [20]Idoko J, Akinsete L, Abalaka A: A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. West Afr J Med 2002, 52:83-86.
• [21]Ibeh BO, Omodamiro OD, Ibeh U, Habu JB: Biochemical and haematological changes in HIV subjects receiving winniecure antiretroviral drug in Nigeria. J Biomed Sci 2013, 20:73. BioMed Central Full Text
• [22]Owiredu WK, Quaye L, Amidu N, Addai-Mensah O: Prevalence of anaemia and immunological markers among ghanaian HAART-naive HIV-patients and those on HAART. Afr Health Sci 2011, 11(1):2-15.
• [23]Zhou J, Jaquet A, Bissagnene E, Musick B, Wools-Kaloustian K, Maxwell N, Boulle A, Wehbe F, Masys D, Iriondo-Perez J, Hemingway-Foday J, Law M, Western Africa, Eastern Africa, Southern Africa, Caribbean and Central and South America, and Asia Pacific Regions of the International Epidemiologic Databases to Evaluate AIDS-IeDEA: Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. J Int AIDS Soc 2012, 15(1):5. BioMed Central Full Text
• [24]Mgogwe J, Semvua H, Msangi R, Mataro C, Kajeguka D, Chilongola J: The evolution of haematological and biochemical indices in HIV patients during a six-month treatment period. Afr Health Sci 2012, 12(1):2-7.
• [25]Johannessen A, Naman E, Gundersen SG, Bruun JN: Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania. BMC Infect Dis 2011, 11:190. BioMed Central Full Text
• [26]Kiragga AN, Castelnuovo B, Nakanjako D, Manabe YC: Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc 2010, 13:42. BioMed Central Full Text
• [27]Tokponnon F, Ogouyémi A, Sissinto Y, Sovi A, Gnanguenon V, Cornélie S, Adéothy A, Ossè R, Wakpo A, Gbénou D, Oke M, Kinde-Gazard D, Kleinschmidt I, Akogbeto MC, Massougbodji A: Impact of long-lasting, insecticidal nets on anaemia and prevalence of Plasmodium falciparum among children under five years in areas with highly resistant malaria vectors. Malar J 2014, 13(1):76. BioMed Central Full Text